Evidence map›Paper›PMID 38698266›Full record

ArticleOncogene2024

CRL2

Saori Motomura, Kanae Yumimoto, Takeshi Tomonaga, Keiichi I Nakayama

Abstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Saori MotomuraDepartment of Molecular and Cellular Biology, Medical Institute of Bioregulation, Kyushu University, Fukuoka, 812-8582, Japan.ORCID 0009-0002-0388-7244
Kanae YumimotoDepartment of Molecular and Cellular Biology, Medical Institute of Bioregulation, Kyushu University, Fukuoka, 812-8582, Japan. tnkana@bioreg.kyushu-u.ac.jp.ORCID 0000-0002-0860-1033
Takeshi TomonagaLaboratory of Proteome Research, National Institutes of Biomedical Innovation, Health, and Nutrition, Ibaraki, Osaka, 567-0085, Japan.
Keiichi I NakayamaDepartment of Molecular and Cellular Biology, Medical Institute of Bioregulation, Kyushu University, Fukuoka, 812-8582, Japan. nakayama.keiichi@tmd.ac.jp.ORCID 0000-0002-7185-1529

Funding

Japan Agency for Medical Research and Development (AMED) JP23ama221119Japan Agency for Medical Research and Development (AMED) JP23ck0106802MEXT | Japan Science and Technology Agency (JST) JPMJFR216GMEXT | Japan Society for the Promotion of Science (JSPS) JP23H00378
6 · The paper itself

Abstract

c-Myc is a proto-oncoprotein that regulates various cellular processes and whose abnormal expression leads to tumorigenesis. c-Myc protein stability has been shown to be predominantly controlled by the ubiquitin ligase (E3) CRL1

Indexed as

F-Box-WD Repeat-Containing Protein 7ProteolysisProto-Oncogene Proteins c-mycUbiquitin-Protein LigasesAnimalsCell Cycle ProteinsCell Line, TumorF-Box ProteinsGlycogen Synthase Kinase 3HumansMiceCell Cycle ProteinsF-Box ProteinsF-Box-WD Repeat-Containing Protein 7FBXW7 protein, humanGlycogen Synthase Kinase 3MYC protein, humanProto-Oncogene Proteins c-mycUbiquitin-Protein Ligases

Identifiers

PMID38698266

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.